Join Sana Health for an exclusive WEBINAR on July 8th at 2:00 PM ET

From Trials to Treatment: Sana Health Prepares for Commercial Leap with DoD Support and VA Integration

Sana Health whose Sana Device is currently in a de novo submission at the FDA for neuropathic pain (NP), Announces that the Department of Defense has just increased its funding for PTSD and other clinical trials. 

Sana is poised to commercialse

Sana health has successful completed a pivotal study in NP (under review at FDA) approval expected Q5 2025

Sana has substantial and increased backing for next indication – PTSD 

Successfully completed a DoD/VA pilot in PTSD – and now DoD is funding $3.9m for a larger PTSD pilot

In addition DoD is funding a further pilot in Adjustment Disorder $500k, and Pain and Sleep $450k

The Sana Device is an at home audiovisual neuromodulation device – usually used at home in bed, to get the user quickly into deep restorative sleep. 

Sana Health is also about to start  (June 19th) a fast confirmatory study in Israel with the largest teaching hospital in Israel. 

The study will be on combat injured veterans with PTSD +Pain. This is expected to result in bulk orders of the Sana device in Q1 2026

This together with early expected sales of the Sana Device for NP  in the Veterans Administration, means Sana is at the great launch point of turning from an R&D to a marketing and sales company.

To learn more please contact Spotlight Family Office Group at Info@SpotlightFamilyOffice.com.